Coenzyme Q10

Clinical Summary

Coenzyme Q10 is a lipophilic benzoquinone that functions as an electron carrier in the mitochondrial electron transport chain (Complex I/II → Complex III) and as a potent lipid-soluble antioxidant. It exists in two interconvertible forms: ubiquinone (oxidized) and ubiquinol (reduced, active antioxidant). Endogenous production declines ~0.7–1%/year after age 30, reaching 40–60% reduction by age 80. Heart, liver, and kidneys have the highest tissue concentrations.

Strongest clinical evidence: Heart failure mortality reduction (43%, Q-SYMBIO trial), migraine prophylaxis (30–40% attack reduction), statin-induced myopathy relief, blood pressure reduction (11 mmHg SBP), and fertility enhancement (both sexes). A landmark N=4,044 pragmatic RCT (NCT06694727, Denmark) is recruiting to definitively confirm the HF benefit — the single largest CoQ10 trial ever registered.

Major 2024–2026 developments: Two independent meta-analyses now support antidepressant/anxiolytic effects (PMIDs 41294251, 40833470) — upgrading depression from "no evidence" to 3/5 (fatigue evidence remains inconclusive per 2026 MA). The FSP1/CoQ10 ferroptosis-suppression axis emerged as a major mechanistic discovery (25 papers in Nature Cell Biology, PNAS, J Hepatol). Sex-specific cardiovascular mortality differences were formally analyzed for the first time (Alehagen 2025, KiSel-10 follow-up).

Who benefits most: Heart failure patients (NYHA II–IV), statin users, migraine sufferers, women with diminished ovarian reserve undergoing IVF, men with idiopathic infertility, and adults >60 with age-related CoQ10 decline.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = causal relationship (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication.

Hard rule: Star rating cannot exceed causal taxonomy ceiling (e.g., SE type caps at 3/5).

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | NE=No evidence/refuted BH: 7–9=strong causal | 5–6=moderate | 3–4=weak | 1–2=speculative Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN See Safety section | AVOID Contraindicated

Star legend: 5/5 Multiple large RCTs + MAs | 4/5 Several human RCTs | 3/5 Some human pilot data | 2/5 Animal/very limited human | 1/5 None/debunked

Prescribing

Dosing Table

Formulation Table

Critical absorption rule: ALL forms require fat for absorption. Taking with 20–30 g dietary fat increases absorption 3–5×. A tablespoon of olive oil or MCT oil with a low-fat meal achieves similar enhancement.

Ubiquinol vs ubiquinone: Marketing claims of 4–8× better bioavailability are not supported. Actual advantage is 1.5–2×. Most landmark trials (Q-SYMBIO, migraine studies) used ubiquinone. Ubiquinol is preferred for elderly and HF patients due to age-related decline in cellular reduction capacity.

Split dosing: For doses >200 mg/d, divide into 2–3 doses. Absorption is saturable — 150 mg BID absorbs more than 300 mg once daily.

No cycling required: CoQ10 does not cause tolerance, receptor desensitization, or suppress endogenous production. Continuous supplementation is standard. Longest safety data: 10+ years without adverse effects.

Condition-Specific Protocols

Heart Failure Protocol

Evidence: 5/5 | Key PMID: 25282031 (Q-SYMBIO)

Phase 1: Initiation (Weeks 1–2)

• 100 mg BID with meals (200 mg/d) — assess tolerance
• Baseline: plasma CoQ10, NT-proBNP, echocardiogram, NYHA class

Phase 2: Therapeutic (Weeks 3–104+)

• 100 mg TID with meals (300 mg/d) — Q-SYMBIO dose
• Target: plasma CoQ10 >2.5 µg/mL
• Reassess NYHA class + functional capacity at 3 mo, 6 mo, then q6mo

Phase 3: Maintenance (Indefinite)

• Continue 300 mg/d if responding; do not discontinue
• NNT for mortality ~14 over 2 years

Drug interaction timing: Safe with ACE-I, ARBs, beta-blockers, diuretics (synergistic). Monitor BP weekly first month if on multiple antihypertensives. Stop/reassess: If no clinical benefit after 6 months at adequate dosing + confirmed plasma levels.

Migraine Prevention Protocol

Evidence: 4/5 | Key PMID: 33402403

Phase 1: Initiation (Month 1)

• 100 mg TID (300 mg/d) or 150 mg BID — with meals

Phase 2: Assessment (Months 2–3)

• Continue 300 mg/d; response is gradual (8–12 wk onset)
• Track: monthly migraine days, attack severity, rescue medication use

Phase 3: Maintenance (Month 4+)

• Continue if ≥50% reduction in attack frequency
• Reassess at 6–12 mo: trial discontinuation if stable

Combination: CoQ10 300 mg + Magnesium 400–600 mg + riboflavin 400 mg (synergistic migraine stack endorsed by AAN/Canadian Headache Society).

Female Fertility (DOR/IVF) Protocol

Evidence: 4/5 | Key PMID: 29587861

Pre-IVF (8–12 weeks before cycle):

• Ubiquinol 200 mg TID (600 mg/d) with meals
• Combine with: DHEA 25–75 mg (under RE supervision), Vitamin D3 2,000 IU, Omega-3 2 g, Myo-Inositol 4 g

Expected outcomes: Improved oocyte quality, higher mature oocyte yield, improved embryo morphology. Best evidence in DOR women (low AMH, high FSH, age >38). Discontinue: Once pregnancy confirmed, unless specific indication (HF, mitochondrial disease).

Safety

Interactions Table

Contraindications

• Absolute: Allergy to CoQ10 (extremely rare)
• Relative: Active chemotherapy without oncologist approval, severe hypotension, warfarin use without INR monitoring
• Pre-surgery: Consider discontinuation 2 wk before major surgery (theoretical bleeding risk)

Adverse Effects

Common (5–10%): GI upset (nausea, diarrhea, stomach discomfort) — take with food, split dose Uncommon (1–2%): Insomnia — take AM/midday, not evening; headache; dizziness (BP lowering) Rare (<0.5%): Skin rash, photosensitivity, paradoxical anxiety/mood disturbance, liver enzyme elevation (reversible) Serious: None reported in trials at doses up to 1,200 mg/d for 16 months. NOAEL 1,200 mg/d. Doses up to 3,000 mg/d studied short-term without toxicity.

FAERS Signal Table (from BioMCP)

FAERS interpretation: 23,061 total FAERS reports for "Coenzyme Q10" + 1,247 for "Ubiquinol." CoQ10 is overwhelmingly listed as concomitant medication in polypharmacy patients with serious conditions (myeloma, PAH, RA). Top reactions (fatigue, GI, headache) reflect underlying diseases and primary drug AEs, not CoQ10 itself. No distinct CoQ10-specific safety signal. This is classic supplement FAERS noise per vault policy (PMID: N/A — FAERS database, accessed 2026-04-16).

Monitoring Table

Special Populations

Renal Impairment

Hepatic Impairment

Pregnancy & Lactation

• Pregnancy: Limited data. No teratogenicity in animal studies. Small human series show safety in early pregnancy (fertility protocols). Use only if clear benefit (pre-existing HF, mitochondrial disease). Dose: 100–200 mg/d max. Obstetric supervision required.
• Lactation: Unknown milk transfer. Large molecular size + lipophilicity suggest minimal. Use lowest effective dose under supervision.
• Pre-conception: Strong evidence for DOR/IVF (600 mg/d ubiquinol). Stop once pregnancy confirmed unless medical indication.

Synergies & Stacking

Named stacks:

• Heart Health: CoQ10 300 mg + Omega-3 2–3 g + Magnesium 400 mg + Selenium 200 mcg
• Statin Protection: CoQ10 100–200 mg + Vitamin D3 2,000 IU + Omega-3 1–2 g
• Migraine Prevention: CoQ10 300 mg + Magnesium 400–600 mg + Riboflavin 400 mg
• Mitochondrial Support: CoQ10 200–300 mg + L-Carnitine 2 g + PQQ 20 mg + Alpha-Lipoic-Acid 600 mg
• Female Fertility: CoQ10 600 mg (ubiquinol) + Myo-Inositol 4 g + Vitamin D3 2,000 IU + Omega-3 2 g
• Male Fertility: CoQ10 200–300 mg + L-Carnitine 2–3 g + Zinc 30 mg + Selenium 200 mcg + Vitamin-E 400 IU

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Note: Pharmacogenomics of CoQ10 response remains critically understudied. No clinical trials have stratified outcomes by genotype. The NQO1 variant is the most clinically actionable but lacks formal validation in supplementation RCTs.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Positive-leaning mixed across ~1,000+ visible reports. CoQ10 is one of the most widely discussed supplements globally.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• Kaneka ubiquinol monopoly: Kaneka Corporation (Osaka) is the sole global manufacturer of ubiquinol. ubiquinol.org is a Kaneka marketing site presented as educational. The "ubiquinol is clearly superior" narrative benefits one company's premium pricing. Actual bioavailability advantage: 1.5–2×, not the 4–8× sometimes claimed.
• Influencer concentration: Broad community discussion — no single influencer dominates. Affiliate links present on most "Best CoQ10" review sites.
• MLM: Herbalife sells CoQ10 through MLM. Standard MLM markup. No CoQ10-specific scam beyond normal MLM concerns.
• Astroturfing: No clear patterns detected. CoQ10 is a commodity supplement from dozens of manufacturers.
• Cymbiotika: Premium "liposomal" products at influencer-driven markup. Pricing not justified by absorption evidence.

Folk vs Clinical Reality Check

Community and clinical evidence ALIGN well on: heart failure benefit, statin myopathy relief, migraine prevention (3-month onset), and fertility enhancement. Major DIVERGENCES: (1) community overestimates ubiquinol superiority (Kaneka marketing effect), (2) community overestimates statin CoQ10 depletion urgency (Cleveland Clinic: "you don't need CoQ10 just because you're on a statin"), (3) community expects subjective energy boost in healthy young people — clinical evidence shows benefit primarily in deficient/depleted populations. The paradoxical anxiety/mood effects reported in communities are clinically underappreciated — only a 2024 ME/CFS study (Olsson, N=120) formally identified depression as a high-dose adverse effect.

Deep Dive: Mechanisms & Research

Primary mechanism: Mobile electron carrier in mitochondrial ETC (Complex I/II → Complex III), driving the proton gradient for ATP synthesis. CoQ10 deficiency reduces ATP production by 25–50%.

Antioxidant defense: Ubiquinol is one of the most potent lipid-soluble antioxidants. Protects LDL from oxidation (early atherosclerosis step), regenerates vitamin E, shields mitochondrial DNA. Operates in lipid bilayers where water-soluble antioxidants cannot reach.

FSP1/ferroptosis axis (2024–2026 discovery): CoQ10 is a key substrate for FSP1 (Ferroptosis Suppressor Protein 1), which reduces CoQ10 to ubiquinol at the plasma membrane to suppress lipid peroxidation-driven ferroptotic cell death. This GPX4-independent anti-ferroptosis pathway was structurally elucidated in 2025 (PNAS, PMID 40440064) and shown to maintain lipid droplet quality control (Nature Cell Biology, PMID 41162632). Implications: CoQ10 may protect against ferroptosis in ischemia-reperfusion injury, neurodegeneration, and cancer contexts — but also means supplementation could theoretically protect cancer cells from ferroptosis-inducing therapies (J Hepatol, PMID 40653112).

Gene expression modulation: Modulates NF-κB, PPAR-α/γ, PGC-1α. Downregulates TNF-α, IL-6, IL-1β. Upregulates endogenous antioxidant enzymes (SOD, catalase, GPx).

Endothelial function: Promotes NO bioavailability, improves endothelium-dependent vasodilation, reduces vascular oxidative stress — explaining BP reduction.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Regulatory Status (from BioMCP)

• FDA: Not approved as drug. Classified as dietary supplement. GRAS status up to 1,200 mg/d. No FDA safety warnings.
• EMA: Not approved as medicinal product. Food supplement classification.
• Japan: Classified as food additive since 2001. Widely available OTC. Kaneka Corporation (Osaka) is the global pioneer and sole ubiquinol manufacturer.
• Regulatory context: CoQ10 is endogenous, present in food, and has no patentable mechanism for any single company — limiting pharmaceutical interest in pursuing drug approval. The NCT06694727 mega-trial may provide evidence for future guideline inclusion.

Ataraxia Verdict (as of 2026-04-16)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to nature (MEDIUM): "CoQ10 is endogenous, therefore safe at any supplemental dose" — endogenous status does not guarantee exogenous safety, though CoQ10's empirical safety record is genuinely excellent
• Hasty generalization (MEDIUM): Ben-Meir 2015 fertility study was primarily preclinical with correlative human data, yet cited as if it were a definitive human RCT
• Cherry-picking (LOW): Q-SYMBIO trial is heavily emphasized; it is a single-center study with N=420. The N=4,044 Danish confirmatory trial will either validate or temper this enthusiasm
• Marketing inflation: Ubiquinol 4–8× bioavailability claims (actual: 1.5–2×); "anti-aging miracle" framing of a compound with zero human longevity data

Evidence Gaps

• Head-to-head formulation trials: Ubiquinol vs ubiquinone vs liposomal on clinical endpoints (not just bioavailability) — the NCT06555575 IVF trial will provide the first head-to-head data
• Pharmacogenomics: No RCTs stratified by NQO1, SOD2, or APOE genotype
• Sex-specific PK: First formal analysis only in 2025; pharmacokinetic data by sex essentially nonexistent
• Long-term safety >10 years: Most studies 6 mo–3 yr; no systematic ultra-long-term tracking
• CNS penetration: Poor BBB crossing may explain negative PD/AD trials; novel formulations with better CNS delivery untested
• Combination therapies: CoQ10 + L-carnitine + ALA factorial RCTs needed
• Dose-response curves: True dose-response rarely established; most studies use fixed doses

Bias Flags (Mode 4: First Principles)

• Assumption: Higher plasma CoQ10 = better clinical outcomes. File's own data notes plasma levels do NOT accurately reflect tissue stores. Supplementation may raise plasma without proportional tissue uptake.
• Assumption: Age-related decline requires supplementation. Decline is documented, but clinical benefit of supplementation in healthy aging is unproven (2/5 — theoretical only).
• Assumption: Ubiquinol is established as superior. Most landmark trials used ubiquinone. The premium pricing of ubiquinol benefits Kaneka's monopoly position.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Kaneka Corporation holds a monopoly on ubiquinol manufacturing. ubiquinol.org is a Kaneka-operated marketing site. Every "ubiquinol is better" claim financially benefits one company. Not fraudulent — product is legitimate — but the narrative is commercially driven.
• Influencer economics: CoQ10 is mainstream enough that no single influencer dominates. Affiliate links are ubiquitous on review sites but not concentrated.
• Counter-narrative manipulation: No significant pharma FUD against CoQ10. It is used as adjunct (not replacement), so it doesn't threaten drug markets.
• Cui bono summary: PRO — Kaneka (ubiquinol monopoly), supplement industry (premium pricing), functional medicine practitioners (protocol component), statin manufacturers (indirectly — CoQ10 as "fix" enables continued statin sales). ANTI — minimal organized opposition; CoQ10 is too well-established and non-threatening to attract pharma counterattacks.
• Red team highlight: The strongest concern is that Q-SYMBIO (the HF mortality trial driving the 5/5 rating) is a single-center study with N=420. If NCT06694727 (N=4,044) returns negative, the entire HF evidence base deflates significantly. Everything else (migraine, fertility, BP) stands independently.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 7/10 — strong evidence for specific indications (heart failure, statin-associated myopathy, migraine, DOR/IVF, male infertility, adults >60); general-population utility under 50 is modest. Indication breadth is wider than most single-target supplements.
• Opportunity cost: $15–45/month; one more pill daily; minimal complexity. Low opportunity cost.
• Verdict: CONDITIONAL
• Conditions: ADD for heart failure (NYHA II–IV), statin users with myopathy, migraine sufferers, women with DOR/IVF, men with idiopathic infertility, adults >60. WATCH LIST for healthy adults <50 without specific indication — revisit when NCT06694727 reports (~2029).

Bottom Line

CoQ10 is one of the best-evidenced supplements in existence, with a genuine mortality benefit in heart failure and meaningful clinical effects in migraine, statin myopathy, hypertension, and fertility. The 2024–2026 literature adds depression/fatigue as emerging indications and reveals a major new mechanism (ferroptosis suppression). Safety is genuinely excellent — no serious signals across decades of use and thousands of FAERS reports. The main caveat: the flagship HF mortality finding rests on a single trial (Q-SYMBIO), and the definitive N=4,044 Danish confirmatory trial won't report until ~2029. For specific indications (HF, statin, migraine, fertility), the evidence already justifies use. For general "anti-aging" supplementation in healthy young adults, the evidence does not yet support routine use.

Practical Notes

Brands & Product Selection

Quality markers: USP Verified, NSF Certified for Sport, ConsumerLab approved. Request Certificate of Analysis (CoA) with lot-matched test results. Kaneka-sourced ubiquinol (Japanese fermentation) preferred over synthetic.

Red flags: No third-party testing, proprietary blends, "miracle cure" claims, MLM-only distribution, suspiciously low price (<$0.05/capsule ubiquinone, <$0.15/capsule ubiquinol), tablets instead of softgels (poor dissolution for fat-soluble compound).

Community-validated brands: Doctor's Best High Absorption (best value ubiquinone), Jarrow QH-Absorb (ubiquinol), Qunol Mega (solubilized), Life Extension Super Ubiquinol (longevity community), Kirkland Signature (Costco — USP verified, best bulk price), Nature Made (USP verified, widely available).

Storage & Handling

Store at 15–25°C, protected from light (amber/opaque container), tightly sealed. Ubiquinol is photosensitive and oxidizes when exposed to light/air. If ubiquinol softgels turn from light yellow/orange to dark brown, they've oxidized — discard. Shelf life: 2–3 yr unopened; 18–24 mo opened (ubiquinone), 12–18 mo opened (ubiquinol). Do not store in bathroom (humidity) or transfer to pill organizers for long-term storage.

Palatability & Compliance

Softgels are tasteless (preferred). Powder is virtually tasteless but slightly chalky. Can mix with smoothies, yogurt, or nut butter. Avoid mixing with boiling liquids (heat degrades CoQ10). The #1 compliance strategy: pair with fattiest meal of the day. Habit-stack with other fat-soluble supplements (D3, E, K2, omega-3).

Exercise & Circadian Timing

No acute ergogenic effect — not a pre-workout supplement. Benefits are from chronic supplementation (4–12 wk). No strong circadian preference, but take AM/midday if insomnia occurs. Can safely take PM with dinner. For athletes, pair with L-Carnitine and Creatine for complementary mitochondrial support.

Reference Ranges (Expected Biomarker Changes)

Cost

Best value: Solubilized ubiquinone provides 2–5× better absorption than standard powder at ~50% higher cost. Cost-per-absorbed-mg: $0.047/mg (solubilized) vs $0.063/mg (standard) vs $0.100/mg (ubiquinol).

What We Don't Know

• Whether the Q-SYMBIO HF mortality benefit replicates in the N=4,044 Danish mega-trial (NCT06694727) — reporting ~2029
• Whether ubiquinol is truly clinically superior to ubiquinone on hard endpoints (first head-to-head IVF trial recruiting: NCT06555575)
• Whether pharmacogenomic variants (NQO1, SOD2, APOE) meaningfully alter supplementation response
• Whether FSP1/ferroptosis suppression is clinically relevant to supplementation or only endogenous CoQ10
• True dose-response curves for most indications (most trials test fixed doses, not dose ranges)
• Long-term effects beyond 10 years of continuous supplementation
• Whether CoQ10 supplementation protects cancer cells from ferroptosis-inducing therapies
• Why a minority of users experience paradoxical anxiety/mood worsening
• Whether CoQ10 extends human lifespan (animal data only; Japanese mouse study PMID 41083029 is first lifetime supplementation study)
• Sex-specific pharmacokinetics (first formal analysis only in 2025)
• Whether CNS-penetrant CoQ10 analogs could succeed where standard CoQ10 failed (PD, AD)
• Whether the KiSel-10 Se+CoQ10 CV mortality benefit is driven by selenium, CoQ10, or the combination

References

Systematic Reviews & Meta-Analyses

• Al Saadi et al. (2021). Cochrane: CoQ10 for heart failure. PMID: 35608922
• Sazali et al. (2021). CoQ10 for migraine prophylaxis — MA. PMID: 33402403
• Qu et al. (2018). CoQ10 for statin-induced myopathy — MA. PMID: 30371340
• Rosenfeldt et al. (2007). CoQ10 for hypertension — MA. PMID: 17287847
• Ho et al. (2016). Cochrane: BP lowering efficacy of CoQ10. PMID: 27017896
• Kim et al. (2021). CoQ10 in T2D — MA of 18 RCTs. PMID: 34273755
• Bakri et al. (2025). CoQ10 for male infertility — MA. PMID: 40878114
• Carnitine + CoQ10 sperm quality — network MA (2025). PMID: 40813743
• CoQ10 on depressive symptoms and fatigue — MA (2026). PMID: 41294251
• CoQ10 on depression and anxiety — MA (2025). PMID: 40833470
• CoQ10 statin-induced myopathy — MA (2025). PMID: 41158831
• CoQ10 on BP and heart rate — MA (2025). PMID: 40495903
• CoQ10 on exercise-induced muscle damage — MA (2025). PMID: 40367843
• CoQ10 analogs exercise oxidative stress — MA (2026). PMID: 41657017
• CoQ10 glycemic control umbrella review (2026). PMID: 41859772
• CoQ10 glycemic control — SR+MA (2026). PMID: 41630501
• CoQ10 metabolic indicators T2D — MA (2025). PMID: 39904656
• CoQ10 lipid/glycemic umbrella review (2024). PMID: 39728267
• CoQ10 DOR/IVF pretreatment — MA (2024). PMID: 39129455
• CoQ10 semen quality + testosterone — MA (2025). PMID: 39830337
• CoQ10 efficacy/safety in HF — MA (2024). PMID: 39462324
• Ubiquinol in heart failure — MA (2024). PMID: 39049769
• CoQ10 exercise performance — MA (2025). PMID: 41457257
• Anthracycline cardiotoxicity prevention — network MA (2025). PMID: 40640889
• CoQ10 periodontal treatment — SR (2025). PMID: 39920883
• Zhang et al. (2023). CoQ10 in PCOS — MA. PMID: 35941510
• Sangouni et al. (2021). CoQ10 in NAFLD — MA. PMID: 33278638
• Amini et al. (2019). CoQ10 post-cardiac surgery AF — MA. PMID: 31949551
• Parohan et al. (2020). CoQ10 migraine — SR. PMID: 30727862
• Migraine prophylaxis dose-response — MA (2025). PMID: 39404918

Landmark RCTs

• Mortensen et al. (2014). Q-SYMBIO: CoQ10 300 mg/d in CHF — 43% CV mortality ↓. PMID: 25282031
• Parkinson Study Group QE3 (2014). High-dose CoQ10 in early PD — NEGATIVE (N=600). PMID: 24664227
• Xu et al. (2018). CoQ10 600 mg/d pre-IVF in DOR — improved pregnancy rates. PMID: 29587861
• Ben-Meir et al. (2015). CoQ10 restores oocyte mitochondrial function. PMID: 26111777
• Wadsworth et al. (2008). CoQ10 in Alzheimer's — NO benefit. PMID: 18590344
• Slater et al. (2011). CoQ10 in adolescent migraine — positive. PMID: 21398419
• Abdollahzad et al. (2015). CoQ10 in RA — ↓ TNF-α, ↓ DAS28. PMID: 26006088
• Singh et al. (1998). CoQ10 post-MI — ↓ cardiac events. PMID: 9707347
• Alehagen et al. (2025). Se+CoQ10 sex differences in CV mortality. PMID: 40563319
• CoQ10 on cardiac function + QoL in HF (2025). PMID: 40507436
• CoQ10 reduces oxidative stress in acute ischemic stroke (2025). PMID: 39999976
• Ubiquinol menstrual symptoms Japan pilot (2025). PMID: 40147024
• CoQ10 + HIIT older adults physical function (2025). PMID: 41470903

Mechanism & Safety

• Crane FL. (2001). Biochemical functions of CoQ10. PMID: 11771674
• Ernster L, Dallner G. (1995). Ubiquinone function review. PMID: 7599208
• Littarru GP, Tiano L. (2007). Bioenergetic/antioxidant properties. PMID: 17914161
• Bhagavan HN, Chopra RK. (2006). CoQ10 pharmacokinetics. PMID: 16551570
• Hidaka et al. (2008). Safety assessment up to 1,200 mg/d. PMID: 19096116
• Hathcock JN, Shao A. (2006). Risk assessment — NOAEL 1,200 mg/d. PMID: 16814439
• Hosoe et al. (2007). Ubiquinol bioavailability. PMID: 17107741
• FSP1 crystal structure + ferroptosis (2025). PMID: 40440064
• FSP1/CoQ10 lipid droplet quality control (2025). PMID: 41162632
• CoQ10 in CV medicine comprehensive review (2026). PMID: 41521431
• Watts et al. (1993). Statin ↓ plasma CoQ10 by 40%. PMID: 8254094
• Fischer et al. (2011). Genetic variants + plasma CoQ10. PMID: 21774831
• KiSel-10: Se+CoQ10 selenoprotein P + telomeres (2024). PMID: 38960007
• KiSel-10: Se+CoQ10 thyroid hormones + CV mortality (2024). PMID: 38714999
• Farhangi et al. (2014). CoQ10 in NAFLD — ↓ ALT, improved HOMA-IR. PMID: 24706027

Disease-Specific

• Roffe et al. (2004). Cochrane: CoQ10 anthracycline cardiotoxicity. PMID: 15266488
• Zhu et al. (2017). CoQ10 Parkinson's review. PMID: 27830343
• Talebi et al. (2024). CoQ10 exercise-induced oxidative damage. PMID: 38479900
• Drobnic et al. (2022). CoQ10 in athletes. PMID: 35565783
• Samimi et al. (2024). CoQ10 in T2D glycemic control. PMID: 38524871
• CoQ10 in cognition review (2025). PMID: 40944284
• Lifetime ubiquinol in mice — aging study (Japan, 2025). PMID: 41083029
• Phase I CoQ10 + doxorubicin PK breast cancer (2025). PMID: 41261512

Guidelines

• AAN/AHS (2012). CoQ10 "possibly effective" Level C for migraine. PMID: 22529203
• Canadian Headache Society (2012). CoQ10 for migraine prophylaxis. PMID: 22683887
• ANMS/CVS (2019). CoQ10 for cyclic vomiting syndrome. PMID: 31241819
• ACC/AHA/HFSA (2022). HF guidelines — CoQ10 NOT included (pending confirmatory mega-trial)
• ESC (2021 + 2023 update). HF guidelines — CoQ10 NOT mentioned